Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
1999-01-20
2002-10-22
Mertz, Prema (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S145100, C424S133100, C424S141100, C424S158100, C424S810000, C424S178100, C530S387300, C530S388100, C530S388230, C530S866000, C530S868000
Reexamination Certificate
active
06468532
ABSTRACT:
FIELD OF THE INVENTION
This application relates to the field of antibody fragments derivatized with polymers, and in particular to the use of such derivatization to increase the circulation half-lives of antibody fragment-polymer conjugates. This application also relates to the field of inflammatory diseases and asthma, and in particular to anti-IL-8 antibody treatment of inflammatory diseases and asthmatic diseases. This application further relates to humanized anti-interleukin-8 (IL-8) antibodies and to high affinity variants of such antibodies.
BACKGROUND
Modification of proteins with polyethylene glycol (“PEGylation”) has the potential to increase residence time and reduce immunogenicity in vivo. For example, Knauf et al.,
J. Biol. Chem.,
263: 15064-15070 (1988) reported a study of the pharmacodynamic behavior in rats of various polyoxylated glycerol and polyethylene glycol modified species of interleukin-2. Despite the known advantage of PEGylation, PEGylated proteins have not been widely exploited for clinical applications. In the case of antibody fragments, PEGylation has not been shown to extend serum half-life to useful levels. Delgado et al.,
Br. J. Cancer,
73: 175-182 (1996), Kitamura et al.,
Cancer Res.,
51: 4310-4315 (1991), Kitamura et al.,
Biochem. Biophys. Res. Comm.,
171: 1387-1394 (1990), and Pedley et al.,
Br. J. Cancer,
70: 1126-1130 (1994) reported studies characterizing blood clearance and tissue uptake of certain anti-tumor antigen antibodies or antibody fragments derivatized with low molecular weight (5 kD) PEG. Zapata et al.,
FASEB J.,
9: A1479 (1995) reported that low molecular weight (5 or 10 kD) PEG attached to a sulfhydryl group in the hinge region of a Fab′ fragment reduced clearance compared to the parental Fab′ molecule.
Interleukin-8 (IL-8) is neutrophil chemotactic peptide secreted by a variety of cells in response to inflammatory mediators (for a review see Hebert et al.
Cancer Investigation
11(6):743 (1993)). IL-8 can play an important role in the pathogenesis of inflammatory disorders, such as adult respiratory distress syndrome (ARDS), septic shock, and multiple organ failure. Immune therapy for such inflammatory disorders can include treatment of an affected patient with anti-IL-8 antibodies.
Sticherling et al. (
J. Immunol.
143:1628 (1989)) disclose the production and characterization of four monoclonal antibodies against IL-8. WO 92/04372, published Mar. 19, 1992, discloses polyclonal antibodies which react with the receptor-interacting site of IL-8 and peptide analogs of IL-8, along with the use of such antibodies to prevent an inflammatory response in patients. St. John et al. (
Chest
103:932 (1993)) review immune therapy for ARDS, septic shock, and multiple organ failure, including the potential therapeutic use of anti-IL-8 antibodies. Sekido et al. (
Nature
365:654 (1993)) disclose the prevention of lung reperfusion injury in rabbits by a monoclonal antibody against IL-8. Mulligan et al. (
J. Immunol.
150:5585 (1993)), disclose protective effects of a murine monoclonal antibody to human IL-8 in inflammatory lung injury in rats.
WO 95/23865 (International Application No. PCT/US95/02589 published Sep. 8, 1995) demonstrates that anti-IL-8 monoclonal antibodies can be used therapeutically in the treatment of other inflammatory disorders, such as bacterial pneumonias and inflammatory bowel disease.
Anti-IL-8 antibodies are additionally useful as reagents for assaying IL-8. For example, Sticherling et al. (
Arch. Dermatol. Res.
284:82 (1992)), disclose the use of anti-IL-8 monoclonal antibodies as reagents in immunohistochemical studies. Ko et al. (
J. Immunol. Methods
149:227 (1992)) disclose the use of anti-IL-8 monoclonal antibodies as reagents in an enzyme-linked immunoabsorbent assay (ELISA) for IL-8.
SUMMARY OF THE INVENTION
One aspect of the invention is a method of treating an inflammatory disorder in a mammal comprising administering to the mammal an effective amount of a conjugate consisting essentially of one or more antibody fragments covalently attached to one or more nonproteinaceous polymer molecules, wherein at least one antibody fragment comprises an antigen binding site that binds to human interleukin-8 (IL-8), and wherein the apparent size of the conjugate is at least about 500 kD.
Another aspect of the invention is a method of treating an asthmatic disorder in a mammal comprising administering to the mammal an effective amount of a conjugate consisting essentially of one or more antibody fragments covalently attached to one or more nonproteinaceous polymer molecules, wherein at least one antibody fragment comprises an antigen binding site that binds to human interleukin-8 (IL-8), and wherein the apparent size of the conjugate is at least about 500 kD.
REFERENCES:
patent: 4002531 (1977-01-01), Royer
patent: 4179337 (1979-12-01), Davis et al.
patent: 4732863 (1988-03-01), Tomasi et al.
patent: 4847325 (1989-07-01), Shadle et al.
patent: 5147537 (1992-09-01), Sada et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5169627 (1992-12-01), Cunningham-Rundles
patent: 5527528 (1996-06-01), Allen et al.
patent: 5532150 (1996-07-01), Snow et al.
patent: 5595732 (1997-01-01), Hakini et al.
patent: 5620689 (1997-04-01), Allen et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5661020 (1997-08-01), Snow et al.
patent: 5670132 (1997-09-01), Griffiths et al.
patent: 5677426 (1997-10-01), Fong et al.
patent: 5679532 (1997-10-01), Repine
patent: 5686070 (1997-11-01), Doerschuk et al.
patent: 5695760 (1997-12-01), Faanes et al.
patent: 5698196 (1997-12-01), Matsushima et al.
patent: 5702946 (1997-12-01), Doerschuk et al.
patent: 5707622 (1998-01-01), Fong et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5874080 (1999-02-01), Hebert et al.
patent: 770628 (1997-05-01), None
patent: WO 92/04372 (1992-03-01), None
patent: WO 94/12219 (1994-06-01), None
patent: WO 94/21235 (1994-09-01), None
patent: WO 95/11987 (1995-05-01), None
patent: WO 95/15769 (1995-06-01), None
patent: WO 95/23813 (1995-09-01), None
patent: WO 95/23865 (1995-09-01), None
patent: WO 95/32003 (1995-11-01), None
patent: WO 95/02576 (1996-02-01), None
patent: WO 96/09325 (1996-03-01), None
patent: WO 96/22785 (1996-03-01), None
patent: WO 96/34015 (1996-10-01), None
patent: WO 96/40731 (1996-12-01), None
patent: WO 97/01354 (1997-01-01), None
patent: WO 97/10847 (1997-03-01), None
patent: WO 97/40215 (1997-10-01), None
patent: WO 98/25971 (1998-06-01), None
patent: WO 98/37200 (1998-08-01), None
patent: WO 99/37779 (1999-07-01), None
Matsumoto et al. Journal of Leukocyte Biology, vol. 62, pp. 581-587, Nov. 1997.*
Kitamura et al. Biochemical and Biophysical Research Communications, vol. 171, No. 3, pp. 1387-1394, Nov. 1997.*
Abuchowski and Davis, “Soluble Polymer—Enzyme Adducts”Enzymes as Drugs, Holcenberg,JS; Roberts,J eds. New York:Wiley, Chapter 13, pp. 367-383 (1981).
Adagen LabelPhysicians' Desk Reference(Product Information), 48 edition, Montvale, NJ:Medical Economics Data Production Company pp. 917=918 (1994).
Allen et al., “A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells”Biochimica et Biophysica Acta1237(2):99-108 (Jul. 26, 1995).
Anderson and Tomasi, “Polymer modification of antibody to eliminate immune complex and Fc binding”Journal of Immunological Methods109(1):37-42 (Apr. 22, 1988).
Beauchamp et al., “A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and &agr;2-macroglobulin”Analytical Biochemistry131(1):25-33 (1983).
Bernard et al., “The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination”American Journal of Respiratory&Critical Care Medicine149(3 Pt 1):818-824 (Mar. 1994).
Brooks and Stocks, Use of polyacrylamide-derivatized antibody in dextran-poly(ethylene glycol) systemsMethods in Enzymology228:390-395 (1994).
Brumeanu et al
Hsei Vanessa
Koumenis Iphigenia
Leong Steven
Presta Leonard
Shahrokh Zahra
Genentech Inc.
Hamud Fozia
Mertz Prema
LandOfFree
Methods of treating inflammatory diseases with anti-IL-8... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating inflammatory diseases with anti-IL-8..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating inflammatory diseases with anti-IL-8... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2957256